Anett Gyurak1, Brian Patenaude2, Mayuresh S Korgaonkar3, Stuart M Grieve3, Leanne M Williams2, Amit Etkin4. 1. Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California; Department of Psychology, Stanford University, Stanford, California; Sierra-Pacific Mental Illness Research, Education, and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California. 2. Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California; Sierra-Pacific Mental Illness Research, Education, and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California. 3. The Brain Dynamics Center, Sydney Medical School, University of Sydney and Westmead Millennium Institute, Sydney, New South Wales, Australia; Discipline of Psychiatry, Sydney Medical School, University of Sydney and Westmead Millennium Institute, Sydney, New South Wales, Australia. 4. Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California; Sierra-Pacific Mental Illness Research, Education, and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California. Electronic address: amitetkin@stanford.edu.
Abstract
BACKGROUND: Despite cognitive function impairment in depression, its relationship to treatment outcome is not well understood. Here, we examined whether pretreatment activation of cortical circuitry during test of cognitive functions predicts outcomes for three commonly used antidepressants. METHODS:Eighty medication-free outpatients with major depression and 34 matched healthy controls were included as participants in the International Study to Predict Optimized Treatment in Depression (iSPOT-D) trial. During functional magnetic resonance imaging, participants completed three tasks that assessed core domains of cognitive functions: response inhibition (Go/NoGo), selective attention (oddball), and selective working memory updating (1-back). Participants were randomized to 1 of 3 arms: escitalopram, sertraline (serotonin-specific reuptake inhibitors [SSRI]), or venlafaxine-extended release (serotonin and norepinephrine reuptake inhibitor [SNRI]) therapy. Functional magnetic resonance imaging scans were repeated after 8 weeks of treatment, and remission was assessed using the Hamilton Rating Scale for Depression. RESULTS: Dorsolateral prefrontal cortex activation during inhibitory "no go" responses was a general predictor of remission, with remitters having the same pretreatment activation as control participants and nonremitters hypoactivating relative to controls. Posttreatment dorsolateral prefrontal cortex activation was reduced in both remitters and controls but not in nonremitters. By contrast, inferior parietal activation differentially predicted remission between SSRI and SNRI medications, with SSRI remitters showing greater pretreatment activation than SSRI nonremitters and the SNRI group showing the opposite pattern. CONCLUSIONS: Intact activation in the frontoparietal network during response inhibition, a core cognitive function, predicts remission with antidepressant treatment, particularly for SSRIs, and may be a potential substrate of the clinical effect of treatment. Published by Elsevier Inc.
RCT Entities:
BACKGROUND: Despite cognitive function impairment in depression, its relationship to treatment outcome is not well understood. Here, we examined whether pretreatment activation of cortical circuitry during test of cognitive functions predicts outcomes for three commonly used antidepressants. METHODS: Eighty medication-free outpatients with major depression and 34 matched healthy controls were included as participants in the International Study to Predict Optimized Treatment in Depression (iSPOT-D) trial. During functional magnetic resonance imaging, participants completed three tasks that assessed core domains of cognitive functions: response inhibition (Go/NoGo), selective attention (oddball), and selective working memory updating (1-back). Participants were randomized to 1 of 3 arms: escitalopram, sertraline (serotonin-specific reuptake inhibitors [SSRI]), or venlafaxine-extended release (serotonin and norepinephrine reuptake inhibitor [SNRI]) therapy. Functional magnetic resonance imaging scans were repeated after 8 weeks of treatment, and remission was assessed using the Hamilton Rating Scale for Depression. RESULTS: Dorsolateral prefrontal cortex activation during inhibitory "no go" responses was a general predictor of remission, with remitters having the same pretreatment activation as control participants and nonremitters hypoactivating relative to controls. Posttreatment dorsolateral prefrontal cortex activation was reduced in both remitters and controls but not in nonremitters. By contrast, inferior parietal activation differentially predicted remission between SSRI and SNRI medications, with SSRI remitters showing greater pretreatment activation than SSRI nonremitters and the SNRI group showing the opposite pattern. CONCLUSIONS: Intact activation in the frontoparietal network during response inhibition, a core cognitive function, predicts remission with antidepressant treatment, particularly for SSRIs, and may be a potential substrate of the clinical effect of treatment. Published by Elsevier Inc.
Authors: Jonathan P Stange; Katie L Bessette; Lisanne M Jenkins; Amy T Peters; Claudia Feldhaus; Natania A Crane; Olusola Ajilore; Rachel H Jacobs; Edward R Watkins; Scott A Langenecker Journal: Hum Brain Mapp Date: 2017-03-27 Impact factor: 5.038
Authors: Leanne M Williams; Mayuresh S Korgaonkar; Yun C Song; Rebecca Paton; Sarah Eagles; Andrea Goldstein-Piekarski; Stuart M Grieve; Anthony W F Harris; Tim Usherwood; Amit Etkin Journal: Neuropsychopharmacology Date: 2015-03-31 Impact factor: 7.853
Authors: Glenda M. MacQueen; Stefanie Hassel; Stephen R. Arnott; Addington Jean; Christopher R. Bowie; Signe L. Bray; Andrew D. Davis; Jonathan Downar; Jane A. Foster; Benicio N. Frey; Benjamin I. Goldstein; Geoffrey B. Hall; Kate L. Harkness; Jacqueline Harris; Raymond W. Lam; Catherine Lebel; Roumen Milev; Daniel J. Müller; Sagar V. Parikh; Sakina Rizvi; Susan Rotzinger; Gulshan B. Sharma; Claudio N. Soares; Gustavo Turecki; Fidel Vila-Rodriguez; Joanna Yu; Mojdeh Zamyadi; Stephen C. Strother; Sidney H. Kennedy Journal: J Psychiatry Neurosci Date: 2019-07-01 Impact factor: 6.186
Authors: Yuen-Siang Ang; Roselinde Kaiser; Thilo Deckersbach; Jorge Almeida; Mary L Phillips; Henry W Chase; Christian A Webb; Ramin Parsey; Maurizio Fava; Patrick McGrath; Myrna Weissman; Phil Adams; Patricia Deldin; Maria A Oquendo; Melvin G McInnis; Thomas Carmody; Gerard Bruder; Crystal M Cooper; Cherise R Chin Fatt; Madhukar H Trivedi; Diego A Pizzagalli Journal: Biol Psychiatry Date: 2020-04-23 Impact factor: 13.382